NASDAQ:ESLA Estrella Immunopharma Q4 2025 Earnings Report $1.00 -0.03 (-2.72%) Closing price 03:59 PM EasternExtended Trading$1.06 +0.06 (+5.79%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Estrella Immunopharma EPS ResultsActual EPS-$0.13Consensus EPS -$0.19Beat/MissBeat by +$0.06One Year Ago EPSN/AEstrella Immunopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEstrella Immunopharma Announcement DetailsQuarterQ4 2025Date11/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEstrella Immunopharma's next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Estrella Immunopharma Earnings HeadlinesEstrella Immunopharma Shareholders Ratify 2026 Auditor Appointment4 hours ago | tipranks.comEstrella Immunopharma (NASDAQ:ESLA) Shares Down 2% - Should You Sell?June 25, 2026 | americanbankingnews.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.June 30 at 1:00 AM | Weiss Ratings (Ad)Estrella Immunopharma Inc.June 9, 2026 | barrons.comEstrella Immunopharma to Participate in the D. Boral Capital Global ConferenceMay 5, 2026 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchMarch 23, 2026 | finance.yahoo.comSee More Estrella Immunopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Estrella Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Estrella Immunopharma and other key companies, straight to your email. Email Address About Estrella ImmunopharmaEstrella Immunopharma (NASDAQ:ESLA), a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.View Estrella Immunopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Wall Street Still Sees Massive Upside for AeroVironment StockManchester United’s Stock Rally Faces a Test Beyond Old TraffordBest Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs ProofPalantir’s Rough 2026 Start Raises a Bigger Question About Its AI MoatWinnebago Misses Estimates, But Surges 14% After EarningsBlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneTrip.com’s Selloff Raises a Bigger Question About Its Travel Recovery Story Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
